Login to Your Account


Alphamab converts CRO platform into drug development engine

By Marie Powers
Staff Writer

Monday, July 14, 2014
Suzhou Alphamab Co. Ltd. is among the new generation of Chinese biopharmas moving rapidly along the evolutionary curve from contract research activities such as high-throughput screening, analytical biology and process development to the construction of a pipeline of biosimilars and, most recently, the development of novel compounds directed at cancer, autoimmune and infectious diseases.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription